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membrane b1-integrins (b1)
d b1 decreases acid ceramidase (Ac), increasing ceramide and
additional b1 accumulation
d Low Ac activity reduces sphingosine (Sp) levels, thereby
impairing bacterial clearance
d Normalizing b1, ceramide, or Sp prevents bacterial infection
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In Brief
Bacterial pneumonia is a major clinical
problem in cystic fibrosis (CF) patients.
Grassme´ et al. show that luminal b1-
integrin accumulation, acid ceramidase
downregulation, increased ceramide, and
the resulting sphingosine depletion in CF
epithelial membranes allows pulmonary
P. aeruginosa infections. Normalizing b1-
integrin prevents bacterial infection in CF
cells and mice.
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Chronic pulmonary colonizationwith bacterial patho-
gens, particularly Pseudomonas aeruginosa, is the
primary cause of morbidity and mortality in patients
with cystic fibrosis (CF). We observed that b1-integ-
rins accumulate on the luminal membrane of upper-
airway epithelial cells from mice and humans with
CF. b1-integrin accumulation is due to increased
ceramide and the formation of ceramide platforms
that trap b1-integrins on the luminal pole of bron-
chial epithelial cells. b1-integrins downregulate acid
ceramidase expression, resulting in further accumu-
lation of ceramide and consequent reduction of
surface sphingosine, a lipid that kills bacteria. Inter-
rupting this vicious cycle by triggering surface b1-in-
tegrin internalization via anti-b1-integrin antibodies
or the RGD peptide ligand—or by genetic or pharma-
cological correction of ceramide levels—normalizes
b1-integrin distribution and sphingosine levels in
CF epithelial cells and prevents P. aeruginosa infec-
tion in CF mice. These findings suggest a therapeu-
tic avenue to ameliorate CF-associated bacterial
infections.
INTRODUCTION
Cystic fibrosis (CF) is the most common autosomal recessive
disorder in the European Union (EU) and the United States
(USA), affecting one of every 2,500 children born in Western
countries. It is caused by mutations of the CF transmembrane
conductance regulator gene (human: CFTR, mouse: Cftr).Cell Host & Microbe 21, 1–1
This is an open access article undAlthough genetic mutations in CFTR lead to several respiratory,
reproductive, and gastrointestinal complications, the primary
cause ofmorbidity andmortality for these patients is the destruc-
tive effects of chronic pulmonary colonization with bacterial
pathogens—in particular, Pseudomonas aeruginosa. Approxi-
mately 80% of CF patients will host P. aeruginosa by the age
of 25 (CF foundation, 2010). In addition to their increased sus-
ceptibility to P. aeruginosa, CF lungs are characterized by
chronic inflammation and progressive fibrosis (Elborn, 2016).
At present, the molecular mechanisms that mediate all three
hallmarks of the disease—i.e., infection, inflammation, and
fibrosis—require further definition.
Because CFTR exhibits chloride-channel activity, it has been
speculated that water absorption by the mucus present on the
epithelial cells of the respiratory tract may be altered and that
this alteration may result in reductions in mucociliary clearance,
a reduced function of defensins, and the ability to eliminate
P. aeruginosa (Matsui et al., 1998). The increased viscosity of
the mucus may also affect the ability of neutrophils to migrate
to and kill bacteria in the respiratory tract (Matsui et al., 2005).
However, although in vitro experiments suggested the concept
of reduced mucociliary clearance in CF, it was difficult to prove
in vivo (Locke et al., 2016). Recent studies have suggested that
one of the leading causes of bacterial infections in CF patients
is an imbalance between pro-inflammatory and anti-inflamma-
tory cytokines in the airways (for review, see Elborn, 2016).
At present, the mechanisms leading to inflammation in CF are
unknown.
We recently reported that, in vitro and in vivo, the lipid
sphingosine efficiently kills many bacterial species, including
P. aeruginosa, Staphylococcus aureus (even MRSA), and Acine-
tobacter baumanii (Pewzner-Jung et al., 2014; Tavakoli Tabaza-
vareh et al., 2016). We found that sphingosine is abundantly
expressed on the luminal surface of human nasal epithelial
cells obtained from healthy persons and from the trachea and2, June 14, 2017 ª 2017 The Authors. Published by Elsevier Inc. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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undetectable on the surface of nasal epithelial cells from individ-
uals with CF and on tracheal and bronchial cells from CF
mice. Inhalation of sphingosine by CF mice eliminated existing
P. aeruginosa infections and prevented new P. aeruginosa or
S. aureus infections in these mice (Pewzner-Jung et al., 2014;
Tavakoli Tabazavareh et al., 2016), a finding demonstrating
that sphingosine plays a key role in the innate and immediate
defense of the upper respiratory tract. Why sphingosine levels
are lower in CF epithelial cells than in healthy cells is presently
unknown.
In contrast, ceramide levels have been shown to be higher
in CF epithelial cells, and pharmacologic or genetic normaliza-
tion of ceramide prevents P. aeruginosa infection in CF mice
(Teichgr€aber et al., 2008; Zhang et al., 2010; Becker et al.,
2010; Brodlie et al., 2010a; Ulrich et al., 2010; Bodas et al.,
2011). Ceramide molecules form small domains in the plasma
membrane; these domains are resolute lipid platforms in an
otherwise dynamic membrane environment and serve to
sequester proteins such as cell-surface molecules (Grassme´
et al., 2001, 2002; Nurminen et al., 2002).
Therefore, we investigated whether ceramide-enriched mem-
brane domains in CF cells mediate an ectopic expression and
function of proteins in CF cells and whether these proteins regu-
late ceramide levels in a vicious cycle, simultaneously controlling
the surface levels of sphingosine in CF epithelia and thereby also
determining infection susceptibility of CF mice and patients.
Here we report that b1-integrins are ectopically expressed on
the luminal pole of CF bronchial, tracheal, and nasal epithelial
cells of individuals and mice with CF but are absent from
such cells in healthy individuals and WT mice. The trapping of
b1-integrins in the luminal membrane of CF bronchial, tracheal,
and nasal epithelial cells is mediated by the accumulation of
ceramide in CF cells. Ectopic b1-integrins in the luminal mem-
brane downregulate the expression of acid ceramidase (Ac) in
human and murine CF airway epithelial cells and thereby
mediate a further accumulation of ceramide and a concomitant
depletion of sphingosine. The vicious cycle between ceramide
and b1-integrin can be blocked by the inhalation of b1-integrin
ligands, which force internalization of b1-integrin and thereby
normalize its surface expression, or by the reduction of cer-
amide levels. Blocking this vicious cycle normalizes sphingo-
sine levels and prevents P. aeruginosa infection of airway
epithelial cells from individuals with CF or pneumonia of CF
mice, respectively.
RESULTS
b1-Integrins Are Ectopically Expressed on the Luminal
Pole of Cystic Fibrosis Cells
Previous studies of the cellular distribution of b1-integrins in
epithelial cells demonstrated that, after synthesis, b1-integrins
are transported to the basolateral and luminal membranes (Gut
et al., 1998). Although they are stably integrated into the basolat-
eral membrane, these integrins are rapidly internalized from the
luminal membrane and degraded, resulting in the absence of
b1-integrins from the luminal membrane (Gut et al., 1998). Our
confocal microscopy studies using the monoclonal anti-b1-
integrin MB1.2 antibody on paraffin-embedded sections from2 Cell Host & Microbe 21, 1–12, June 14, 2017the lungs of WT mice confirm the absence of b1-integrins on
the luminal surface of WT bronchial epithelial cells (Figures 1A
and S1A). In contrast, we observed a marked luminal presenta-
tion of b1-integrins on bronchial epithelial cells in CFMHH (Figures
1A and S1A) or Cftr/mice (not shown). Here, and in all studies
below, we used two CF mouse strains—i.e., CFMHH mice, which
have a residual activity of Cftr, and Cftr/ mice, which lack Cftr
in the lung but express a CFTR transgene in the gut under control
of the fatty-acid-binding protein promoter. Both strains can be
fed with a normal diet and do not show any developmental retar-
dation. In our studies, we did not notice any differences between
the two strains as detailed below.
Ectopic luminal expression of b1-integrins on bronchial
epithelial cells in CF lungs in vivo was confirmed by intratracheal
injection of the anti-b1-integrin antibody 9EG7 into the lungs of
Cftr/ mice, followed by lavage, in situ fixation, and staining
with Cy3-coupled anti-rat antibodies, which bind to the anti-
b1-integrin antibodies already present in the airways (Figures
1B and S1B). Similar results were obtained with CFMHH mice.
Because the 9EG7 monoclonal antibody binds to the active
conformation of b1-integrin (Lenter et al., 1993), these findings
suggest that the ectopically expressed b1-integrin is active
either in the extended closed or open state. We also confirmed
surface expression of b1-integrin by immunoprecipitating sur-
face b1-integrin from the intact surface of CF tracheae with
anti-b1-integrin antibodies (clone MB1.2) that detect all confor-
mations of b1-integrin (Figures 1C and S1C).
Control stainings with rat isotype control antibodies to the
b1-integrin antibodies (Figures S1A and S1B) or just with Cy3-
coupled anti-rat antibodies (not shown) confirmed the specificity
of the stainings. Quantification of four independent immunopre-
cipitation experiments confirms the fluorescence microscopy
data (Figure S1C). Further controls stainedwith Cy3-coupled An-
nexin V to detect phosphatidylserine in the membrane revealed
no difference in the intensity of the stainings between CF and
WT mice (Figure S1D). The ratio of the fluorescence intensities
of surface b1-integrin and Cy3 annexin in CF and WT airways
(Figure S1E) confirms the notion of accumulation of b1-integrin
in the luminal membrane of bronchial and tracheal epithelial cells
of CF mice. Further, we stained WT and CF lung sections with
anti-b2-integrin antibodies and did not detect a difference be-
tween WT and CF airways (Figure S1F). The anatomical struc-
tures are displayed in Figure S1G. In summary, these experi-
ments demonstrate that b1-integrins are ectopically expressed
on the luminal membrane of tracheal and bronchial epithelial
cells from CF mice in vivo.
Ceramide Mediates Ectopic Expression of b1-Integrins
in Cystic Fibrosis Cells
Next, we investigated whether ceramide mediates the ectopic
expression of b1-integrins and whether normalization of cer-
amide concentrations in CF mice alters the surface expres-
sion of b1-integrins. We have previously shown that ceramide
clusters and activates b1-integrins in B16F10 melanoma cells
(Carpinteiro et al., 2015). We confirmed previous findings
(Teichgr€aber et al., 2008) of high ceramide expression in
bronchi of Cftr/ mice (Figures 2A and S1H) or CFMHH mice
(not shown). Reducing acid sphingomyelinase (Asm) activity by
treating Cftr/ mice with amitriptyline or fluoxetine, which are
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Figure 1. Cystic Fibrosis Bronchial Epithelial Cells Ectopically Express Luminal b1-Integrin
(A) Murine cystic fibrosis (CF) bronchial epithelial cells ectopically present b1-integrin on their luminal pole, whereas b1-integrin is absent from wild-type (WT)
bronchi. Luminal integrins are indicated by arrows; E, bronchial epithelial cell layer; L, bronchial lumen. Paraffin-embedded sections from WT and CFMHH lungs
were stained with Cy3-coupled anti-b1-integrin antibodies and analyzed by confocal microscopy. The topology of the epithelial cell layer is illustrated on one cell
(luminal surface in yellow). Representative results from six mice are shown.
(B) Intrapulmonary injection of anti-b1-integrin antibodies into Cftr/ mice confirms luminal expression of b1-integrin in CF bronchial epithelial cells in vivo,
whereas luminal b1-integrin is not expressed in WT bronchi. Representative results from six mice are shown.
(C) Immunoprecipitation of b1-integrin from the intact surface of the trachea reveals ectopic luminal expression of b1-integrin in the trachea of CFMHH and Cftr/
mice, but not in WT trachea. Up: unspecific immunoprecipitation with an irrelevant isotype control antibody. Results are representative of four similar
experiments.
Please see also Figure S1.
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thereby reduce ceramide in CF tissues (Teichgr€aber et al.,
2008; Becker et al., 2010; Hurwitz et al., 1994; Kornhuber
et al., 2010), or by genetic heterozygosity of Asm normalizes cer-
amide levels (Figures 2A and S1H) as well as the subcellular dis-
tribution pattern of b1-integrins (Figures 2B and S1I) in murine CF
bronchial epithelial cells. Ceramide has been previously shown
to cluster cell-surface receptors, contributing to the amplification
of signal transduction (Grassme´ et al., 2001). Therefore, we
investigated whether ceramide and b1-integrins co-cluster in
CFmice. Confocal microscopy of bronchi fromCftr/mice (Fig-
ure 2C) or CFMHH mice (not shown) demonstrated clustering of
b1-integrin in luminally expressed ceramide-enriched mem-
brane platforms. Collectively, these findings demonstrate that
ceramide plays a crucial role in the aberrant luminal presentation
of integrins on bronchial epithelial cells in CF mice.
To further investigate the role of ceramide in the ectopic
luminal upregulation of b1-integrins by an experimental
approach independent of Cftr deficiency, we used overexpress-ing Asm-transgenic and heterozygous Ac-deficient mice. These
mice accumulate ceramide in the lungs, in particular in bronchial
epithelial cells (Figure 2D), and show a distinctive increase in the
expression of luminal b1-integrin in the bronchial epithelial cells
of each genetic variant (Figure 2E), a finding indicating a direct
and causal link between ceramide accumulation and the ectopic
localization of luminal b1-integrin in the mouse lung. As is true in
CF mice, the pharmacologic reduction of ceramide levels in
Asm-transgenic and Ac-heterozygous mice upon treatment
with amitriptyline normalized the expression of b1-integrin. The
fluorescence studies were also quantified (Figures S1J and S2A).
Normalization of Luminal b1-Integrin Expression Also
Normalizes Ceramide Levels in Cystic Fibrosis Airways
It has been previously shown that binding b1-integrins with anti-
bodies or arginine-glycine-aspartate (RGD) peptides results in
internalization of the integrin molecule (Tran Van Nhieu and Is-
berg, 1993; Ye et al., 2006). Thus, to achieve internalization of
the ectopically expressed surface b1-integrins on CF airways,Cell Host & Microbe 21, 1–12, June 14, 2017 3
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Figure 2. Luminal b1-Integrin Expression Is Caused by Accumulation of Cell-Membrane Ceramide
(A and B) Epithelial cells in bronchi of CF mouse (Cftr/) lungs accumulate higher levels of ceramide than healthy human or WT mouse cells. Heterozygosity
or pharmacological inhibition of acid sphingomyelinase (Asm) corrects ceramide accumulation in Cftr/ bronchial epithelial cells (A) and ectopic expression of
b1-integrin on the cell lumen (B). Lung sections were stained with Cy3-coupled anti-ceramide or anti-b1-integrin antibodies and analyzed by confocal micro-
scopy. The topology of a representative cell is indicated (luminal surface in yellow).
(C) Lung sections from Cftr/ mice stained with Cy5-coupled anti-ceramide and Cy3-labeled anti-b1-integrin antibodies demonstrate co-localization of cer-
amide and b1-integrin.
(D) Ceramide also accumulates in the lungs of acid sphingomyelinase (Asm)-transgenic and heterozygous acid ceramidase (Ac)-deficient mice. This accumu-
lation of ceramide is associated with luminal expression of b1-integrin in both genetic variants. Pharmacologic reduction of Asm attenuates surface expression of
b1-integrin in Asm-transgenic or Ac-heterozygous mice. Please see also Figures S1 and S2.
Results are representative of experiments using at least six mice per group in (A)–(C) or four mice per group in (D) and (E). E, epithelial cell layer; L, lumen. Arrows
indicate ceramide-enriched membrane platforms in (A), (C), and (D) and indicate b1-integrin cluster in (B), (C), and (E). Please note that ceramide staining in the
alveoli did not differ betweenWT and CFmice, consistent with the expression of CF. Not all samples show alveoli around the bronchi. In D (WT), the epithelial cell
layer and a large blood vessel are shown, while the other photos show epithelial cells and alveoli.
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(Figure 3B) either to inhalation of nebulized anti-b1-integrin
antibody clone 9EG7, which binds the partly or fully active
conformation of b1-integrin molecules (Lenter et al., 1993), or
to inhalation of RGD peptides, which bind to the fibronectin bind-
ing site of the receptor (D’Souza et al., 1988). Inhalation of 0.9%
NaCl, isotype control antibodies or scrambled peptides served
as controls.
Inhalation of RGD peptides and anti-b1-integrin antibodies
(clone 9EG7) normalized tracheal and bronchial surface expres-
sion of b1-integrin, whereas inhalation of control reagents had
no effect (Figures 3A, 3B, and S2B; Table S1). Inhalation of fluo-4 Cell Host & Microbe 21, 1–12, June 14, 2017rescein isothiocyanate (FITC)-coupled RGD peptides confirmed
the rapid uptake of b1-integrin into the cells upon ligand binding
(Figure 3C). Normalization of luminal b1-integrin levels also
normalized surface ceramide levels in the trachea and the
bronchi of CF mice (Figures 3D, 3E, and S2B). These findings
suggest a vicious cycle between surface ceramide and b1-
integrin.
Ectopically Expressed b1-Integrin Downregulates Ac
Expression
To test whether ectopic expression of b1-integrin regulates the
lipid phenotype in CF airways, we measured the expression
Figure 3. Normalization of b1-Integrin Expression and Ceramide Levels by Inhalation of Anti-b1-Integrin Antibodies or Arginine-Glycine-
Aspartate Peptides
(A) Subjecting cystic fibrosis (Cftr/) mice to inhalation of nebulized anti-b1-integrin 9EG7 antibodies or arginine-glycine-aspartate (RGD) peptides normalizes
the expression of ectopic integrins in the trachea and bronchi of CF mice. Surface b1-integrin is indicated by arrows.
(B) Ectopic surface expression of b1-integrin and its downregulation upon inhalation of RGD peptides or anti-b1-integrin 9EG7 antibodies (a-Int-Ab), but not by
the appropriate control antibodies (ctr. Ab.) or control peptides (ctr. peptide), was confirmed by immunoprecipitation of surface b1-integrin, as above.
(C) Inhaled fluorescein isothiocyanate (FITC)-conjugated RGD is rapidly internalized. WT or Cftr/ (CF) mice were subjected to inhalation with FITC-conjugated
RGD, and tracheal epithelial cells were isolated and analyzed by confocal microscopy.
(D and E) The expression levels of ceramide are normalized by inhalation of RGD peptides or anti-b1-integrin 9EG7 antibodies (anti-Int. Ab), as measured by
immunostaining and confocal microscopy (D) or by in situ kinase assays measuring surface ceramide levels, while control (ctr.) peptides or antibodies were
without effect (E).
E, bronchial epithelial cell layer; L, bronchial lumen. Shown are typical results from one of six independent studies (A–D). (E) shows the mean ± SD, n = 6, ANOVA,
overall p < 0.001. Please see also Figures S2 and S3 and Table S1.
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either RGD peptides or anti-b1-integrin antibodies.
Fluorescencemicroscopy, western blot studies, and in situ ac-
tivity measurements of Ac in the trachea showed largely reduced
expression of Ac in trachea and large bronchi of Cftr/ mice, in
particular in the cilia and the luminal membrane of epithelial cells
(Figures 4A–4C and S2C; Table S2). Inhalation of RGD peptides
or anti-b1-integrin antibodies normalized the expression of Ac
(Figures 4A–4C and S2C; Table S2). In accordance with these
findings, the activity of Ac, as measured in vivo on the surface
of the trachea, was greatly reduced in Cftr/ mice and was
only slightly further reduced by incubating the trachea with Ac in-
hibitors, which reduced the activity of Ac in WT trachea to the
level of that observed in Cftr/mice (Figure 4D). Finally, inhala-tion of RGD peptides or anti-b1-integrin antibodies normalized
the levels of sphingosine in CF airways (Figures 4E, 4F, and
S2D). These findings suggest that ectopically expressed b1-in-
tegrin regulates ceramide and sphingosine by downregulating
Ac levels in CF cells.
Further studies (Figures S2E–S2G, S3A–S3H, S4A, and S4B)
addressed mechanisms of ceramide-mediated trapping of b1-
integrin and show (1) that internalization of a GPI-linked protein,
Art1, is not sufficient to trigger internalization of b1-integrin and
does not alter ceramide and sphingosine concentrations in CF
cells (Figures S2E–S2G); (2) that ceramide itself prevents rapid
degradation and internalization of b1-integrin (Figures S3A and
S3B; Tables S3 and S4); (3) that infection with P. aeruginosa ac-
tivates the acid sphingomyelinase but has almost no impact onCell Host & Microbe 21, 1–12, June 14, 2017 5
Figure 4. Expression of Acid Ceramidase Is Reduced in Cystic Fibrosis Mice and Is Corrected by Normalization of b1-Integrin Expression
(A) Mice were subjected to inhalation procedure as indicated. The trachea was removed after 2 hr, fixed, embedded in paraffin, sectioned, dewaxed, and stained
with Cy3-coupled anti-acid ceramidase (Ac) antibodies. Expression of Ac is much lower in cystic fibrosis (CF) cells (Cftr/) than in WT cells and is corrected by
inhalation of either arginine-glycine-aspartate (RGD) peptides or anti-b1-integrin (Int) antibody 9EG7 (anti-Int), but is left unaltered by inhalation of control (ctr)
peptides (pep) or antibodies (Ab). Figures are representative of six independent studies with similar results.
(B) Greater magnification shows luminal expression of Ac in epithelial cells of WT mice and absence of Ac in Cftr/ cells. Arrows indicate areas with high
expression of Ac.
(C) WT or Cftr/ mice were left untreated or subjected to inhalation of RGD peptides, control (ctr) peptides, anti-b1-integrin, or isotype control anti-
bodies. Tracheal epithelial cells were isolated and subjected to western blot analysis. These studies demonstrate a marked downregulation of Ac in CF
cells; this is corrected after binding and normalization of b1-integrin surface expression. Figures are representative of four independent studies with similar
results.
(D) Surface activity of Ac in the trachea was measured by injection of 4 mL [14C16]-ceramide into the lumen of the trachea of anesthetized mice in the presence or
absence of an Ac inhibitor—either N-oleoylethanolamine (NOE) or carmofur (Car). Mean ± SD, n = 4, *p < 0.05; t test.
(E) Sphingosine levels are markedly reduced in CF airways. Inhalation of nebulized anti-b1-integrin antibodies or RGD peptides normalizes the expression
of surface sphingosine in the trachea and bronchi of CF mice. Sphingosine was visualized by staining with Cy3-coupled anti-sphingosine antibodies. The
specificity of the anti-sphingosine antibodies had been previously confirmed (Pewzner-Jung et al., 2014). Shown are representative results from six independent
experiments.
(F) Surface sphingosine levels were quantified on the luminal membrane of the trachea by in situ kinase assays. Means ± SD, n = 6, ANOVA, overall p < 0.001. E,
bronchial epithelial cell layer; L, bronchial lumen. Please see also Figures S3 and S4 and Tables S3 and S4.
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ligand to b1-integrin is sufficient to mediate its internalization,
and is followed by re-expression of acid ceramidase and normal-
ization of surface ceramide levels (Figures S3E–S3H); (5) that
internalization of b1-integrin is required to trigger these events
(Figures S3E–S3H); and (6) that b1-integrin physically interacts
with ceramide-enriched membrane platforms (Figures S4A
and S4B).6 Cell Host & Microbe 21, 1–12, June 14, 2017Binding and Internalization of Luminal b1-Integrins
Prevent P. aeruginosa Infection in Cystic Fibrosis Mice
CF mice (CFMHH and Cftr/), overexpressing Asm-transgenic
mice, and heterozygous Ac-deficient mice were all very sucepti-
ble to acute or chronic infection with non-mucoid and mucoid
P. aeruginosa (Figures 5A–5D and Figures S4C–S4E). Inhalation
of anti-b1-integrin antibodies or RGD peptides rescued each
mouse strain from infection with P. aeruginosa (Figures 5A–5D
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Figure 5. Inhalation of Anti-b1-Integrin
Antibodies or RGD Peptides Prevents Pseu-
domonas aeruginosa Infection in Cystic
Fibrosis Mice In Vivo
(A–D) Inhalation of either nebulized anti-b1-integrin
antibodies (Ab) or RGD peptides or Asm-hetero-
zygosity prevents pulmonary infection in cystic
fibrosis (CF), acid sphingomyelinase (Asm)-trans-
genic, or heterozygous acid ceramidase (Ac)-
deficient mice (A). (Sub-)chronic or acute infection
of CF mice with mucoid P. aeruginosa strains 1242
or 1245 is eliminated by inhalation of Ac, sphin-
gosine (SPH) or RGD-peptides. Mice were intra-
nasally infected with 53 107 CFU of P. aeruginosa
strain 762 (A), five times every 24 hr with 1 3 107
CFU of P. aeruginosa strains 1242 or 1245 (B and
C) or once with 5 3 107 CFU of P. aeruginosa
strains 1242 or 1245 (D). Anti-b1-integrin anti-
bodies, Ac, SPH, or RGD peptides were inhaled
1 hr prior to infection with P. aeruginosa strain 762
(A) or either 1 hr or 48 hr after the last or 1 hr prior
to infection with 1242 or 1245 (B–D). Pulmonary
CFUs were determined 4 hr after infection (A)
or either 6 hr or 96 hr after infection (B–D). Inha-
lation of 0.9% NaCl, control peptides, or isotype-
matched antibodies (Ab) did not alter the infection
with P. aeruginosa compared to untreated mice.
Mean ± SD, n = 6, ANOVA, overall p < 0.001.
Please see also Figures S4, S5, and S6.
Please cite this article in press as: Grassme´ et al., b1-Integrin Accumulates in Cystic Fibrosis Luminal Airway Epithelial Membranes and Decreases
Sphingosine, Promoting Bacterial Infections, Cell Host & Microbe (2017), http://dx.doi.org/10.1016/j.chom.2017.05.001and S4C–S4E). Heterozygosity of the acid sphingomyelinase in
CF mice normalized the infection susceptibility of these mice,
confirming previous findings (Figures 5A and S4C; Teichgr€aber
et al., 2008). Control peptides or isotype-matched irrelevant anti-
bodies did not alter themassive infection of thesemouse strains.
Incubation of P. aeruginosa with anti-b1-integrin antibodies or
RGD peptides prior to intranasal application did not alter the
infection (data not shown); this finding excludes the possibility
that the protective effect of these treatments is due to direct bind-
ing of the agents to bacterial proteins. Inhalation of sphingosine,
Ac, or RGD also cured or prevented, respectively, (sub-)chronic
or acute infections with two mucoid P. aeruginosa strains,
1242 and 1245 (Figures 5B–5D). Inhalation of sphingosine,
Ac, or RGD peptides 1 hr after the infection also preventedCellmortality of CF mice pulmonarily infected
with P. aeruginosa strains 762, ATCC
27853, 1242, or 1245 (Figure S4F).
Conversely, the inhalation of anti-sphin-
gosine antibodies by WT mice greatly
sensitized them to P. aeruginosa infection
(Figure S4G).
Histology studies confirm killing
of P. aeruginosa strains 762, ATCC
27853, 1242, and 1245 upon inhalation
of RGD-peptides, anti-b1-integrin anti-
bodies, sphingosine, or acid ceramidase;
they also confirmed rapid resolution of
the inflammation in these animals. While
infected, untreated CF mice suffer from
severe pneumonia (Figures S5A–S5D;
data not shown). In vitro and in vivostudies with micellar sphingosine or isolated tracheal surfaces
from WT or CF mice incubated with Ac, sphingosine, or controls
revealed that surface sphingosine kills planctonic and mucoid
P. aeruginosa strains (Figures S6A–S6F).
Ectopic Expression of b1-Integrins Causes Ac
Downregulation, Sphingosine Downregulation, and
Infection Susceptibility in Human Airway CF Cells
b1-integrin was also ectopically expressed on the luminal sur-
face of bronchi, nasal polyps, and in isolated nasal epithelial cells
from CF patients, while b1-integrin was absent from the surface
of healthy controls (Figures 6A–6C). Incubation with Ac-degrad-
ing ceramide normalized expression of b1-integrin (Figure 6C).
Ac and sphingosine were downregulated in CF bronchial andHost & Microbe 21, 1–12, June 14, 2017 7
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Figure 6. Ectopic Expression of b1-Integrins Causes Acid Ceramidase Downregulation in Human Airway CF Cells
(A–C) Ectopic surface expression of b1-integrin is found on the luminal pole of human CF bronchial epithelial cells (A), epithelial cells of nasal polyps (B), and
freshly isolated nasal epithelial cells (C) but is absent from the luminal side of epithelial cells from healthy persons. Incubation with RGD peptides, anti-b1-integrin
(Int) antibodies (HUTS-4), or acid ceramidase (Ac) normalized expression of b1-integrin in CF nasal epithelial cells (C). Sections from human CF or donor lungs or
nasal polyps or freshly isolated, intact nasal epithelial cells were stained with Cy3-coupled anti-b1-integrin antibodies (Abcam) and analyzed by confocal mi-
croscopy. Shown are representative results from each of five CF or four healthy individuals (A and C) or each of four CF or healthy persons (B).
Ac expression is downregulated in CF bronchial and nasal epithelial cells compared to healthy controls, (D) and (E). Normalization of ectopic b1-integrin
expression resulted in re-expression of Ac (E). Fluorescence intensities in the luminal membrane were quantified using ImageJ and are given in arbitrary units
(a.u.). Mean ± SD; n = 4 or 5; p values as given; t test for comparison of two values and ANOVA and post hoc Student’s t tests for all pairwise comparisons,
applying Bonferroni correction for multiple comparisons. Overall p value for ANOVA is < 0.001 in all panels. The luminal membrane is indicated by arrows;
E = epithelial cell layer. Please see also Figure S7.
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Sphingosine, Promoting Bacterial Infections, Cell Host & Microbe (2017), http://dx.doi.org/10.1016/j.chom.2017.05.001nasal epithelial cells compared to healthy controls (Figures 6D,
6E, and 7A–7C), while ceramide was severely upregulated
(Figures S7A–S7C). Normalization of ectopic expression of
b1-integrin in CF nasal epithelial cells by forced internalization
of b1-integrin upon incubation of isolated nasal epithelial cells
with anti-b1-integrin antibodies or RGD-peptides mediated re-
expression of Ac and normalized both sphingosine and ceramide
levels in CF cells (Figures 6E, 7A, 7C, and S7B). We used the
HUTS-4 anti-b1-integrin antibody, which binds to the active
form of b1-integrin, confirming the previous notion that ectopic
surface b1-integrin is active. Conversely, application of Ac
normalized the ectopic expression of b1-integrin in CF cells (Fig-
ure 6C) as well as the sphingosine and ceramide levels (Figures
7A, 7C, and S7B). Inhalation of sphingosine restored surface
sphingosine levels in CF airway cells (Figure 7A).8 Cell Host & Microbe 21, 1–12, June 14, 2017CF nasal epithelial cells had a reduced capability to kill
P. aeruginosa, which were readily killed by nasal epithelial cells
from healthy controls (Figure S7D). Pre-incubation of CF nasal
epithelial cells with anti-b1-integrin antibodies (HUTS-4), RGD-
peptides, acid ceramidase, or sphingosine restored killing of
P. aeruginosa by these cells (Figure S7D). Finally, we confirmed
the reduction of Ac activity in cultured primary bronchial epithe-
lial cells from people with CF compared to cells from non-CF in-
dividuals (Figure S7E).
DISCUSSION
Our studies have identified a mechanism that explains the high
susceptibility of CF patients and mice to acute infections with
P. aeruginosa. We assume the following scenario: ceramide
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Figure 7. Ectopic Expression of b1-Integrins Reduces Acid Ceramidase Activity and Sphingosine and Increases Ceramide Levels in Human
Airway CF Cells
(A–C) Ac activity (A) and sphingosine (A–C) are downregulated in CF bronchial (B) and nasal epithelial cells (A andC) compared to healthy controls, while ceramide
(A) is severely upregulated. Normalization of ectopic b1-integrin expression by treatment with RGD peptides or anti-b1-integrin (antibodies (HUTS-4) resulted in
normalization of Ac activity (A), re-expression of sphingosine (A–C), and reduction of ceramide (A) levels in CF cells. Incubation of freshly isolated epithelial cells
with Ac normalized sphingosine (A and C) and ceramide (A) levels. Treatment with sphingosine restored surface sphingosine (SPH) levels (A). Sections (B) or cells
(C) were stained as indicated with Cy3-labeled anti-sphingosine antibodies. Pre-incubations were performed with RGD peptides, HUTS-4 anti-b1-integrin an-
tibodies (a-Int-Ab), Ac, or sphingosine as indicated. (A) Mean ± SD; n = 4 or 5; p-values are indicated; t-test for comparison of two values; ANOVA and post-hoc
Student’s t-tests for all pairwise comparisons, applying Bonferroni correction for multiple comparisons. Overall p-value for ANOVA is <0.001 in all panels. (B) The
luminal membrane is indicated by arrows; E = epithelial cell layer. Please see also Figure S7.
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Sphingosine, Promoting Bacterial Infections, Cell Host & Microbe (2017), http://dx.doi.org/10.1016/j.chom.2017.05.001accumulation in CF cells results in trapping and ectopic surface
expression of b1-integrins and thereby in downregulation of Ac
protein expression via still-unknown mechanisms. The downre-
gulation of Ac expression results in a feed-forward cycle of addi-
tional ceramide formation and b1-integrin clustering but also
in a marked reduction of sphingosine levels. Increased cer-
amide levels also trigger the activation of CD95 and thereby
mediate increased death of epithelial cells, as previously shown
(Teichgr€aber et al., 2008; Becker et al., 2012). Finally, the combi-
nation of low sphingosine concentrations and increased release
of dead cells or DNA from the epithelial cell layer into the lumen
causes the high susceptibility to infection. In this scenario, sphin-
gosine is the first line of defense, whereas DNA greatly facilitates
infection with bacteria, if the bacteria reach the lung, because
of the low sphingosine levels in the upper airways. Thus, normal-
ization of the levels of b1-integrin, ceramide, or sphingosine pre-
vents infection.
Sphingosine is also downregulated in the airways of mice after
severe burn injury and prevents pulmonary P. aeruginosa infec-tions of these mice (Rice et al., 2016). Alterations in sphingolipid
metabolism have also been implicated in chronic obstructive
pulmonary disease (COPD) (Petrache et al., 2005), a disease
that is very often associated with chronic infections with
P. aeruginosa (Lieberman and Lieberman, 2003). A role of sur-
face b1-integrin expression in these diseases remains to be
determined.
The important role of the upper airways in bacterial defense is
highlighted by the clinical finding that successful management of
the sinuses prior to and after lung transplantation of CF patients
(i.e., with lungs with normal expression of Cftr) greatly reduces
the incidence of acute pneumonia compared to CF patients
without sinus management (Holzmann et al., 2004; Vital
et al., 2013).
A recent study found that CF mice lack the ATP12A channel;
this deficiency results in a higher resistance to chronic bacte-
rial infections than is found in pigs or in patients with CF that
express ATP12A (Shah et al., 2016). Thus, although the lungs
of CF mice contain approximately 100 CFU 3 days afterCell Host & Microbe 21, 1–12, June 14, 2017 9
Please cite this article in press as: Grassme´ et al., b1-Integrin Accumulates in Cystic Fibrosis Luminal Airway Epithelial Membranes and Decreases
Sphingosine, Promoting Bacterial Infections, Cell Host & Microbe (2017), http://dx.doi.org/10.1016/j.chom.2017.05.001exposure to bacteria, they contain 10,000 CFU at the same
time point if ATP12A is expressed in the lung by adenoviral
infection (Shah et al., 2016). Our studies with repeated applica-
tion of mucoid P. aeruginosa strains show higher bacterial
numbers with 6,000 and 8,000 CFU in the lung of CF mice,
and the mucoid strains might be less affected by the pH regu-
lation in the airways. It will be very interesting to study the rela-
tion between ATP12A and b1-integrin-acid-ceramidase and
sphingosine.
b1-integrin exists in three conformations: the inactive bent
state, the extended closed state, and the extended open state
(Su et al., 2016). The 9EG7 antibody binds to the integrin-
epidermal growth factor domain 2 (I-EGF2), which is exposed
in the extended closed or open state, within the b1-integrinmole-
cule, while ligands such as RGD bind to the head of the integrin
molecule (Lenter et al., 1993; Su et al., 2016). Thus, ceramide or
ceramide-enriched membrane domains trap inactive b1-integrin
and seem to induce a conformational change to the active
extended closed domain. This is insufficient to induce internali-
zation, but allows binding of the 9EG7 antibody. Subsequent
binding of RGD peptides or 9EG7 antibodies to b1-integrin in-
duces and stabilizes the extended open conformation of the
molecule, which is fully active and internalized. A similar stabili-
zation of the active conformation might be achieved by binding
of the anti-human-b1-integrin antibody HUTS4, thereby trig-
gering internalisation.
In contrast to the studies by Teichgr€aber et al. (2008);
Zhang et al. (2010); Becker et al. (2010); Ulrich et al. (2010);
Brodlie et al. (2010a); Bodas et al. (2011); Caretti et al. (2014); Ito-
kazu et al. (2014), and Quinn et al. (2016); Guilbault et al. (2009)
described a a decrease of ceramide in CF and an increase of
dihydro-ceramide. This might be explained by technical differ-
ences, since Guilbault et al. (2009) used an ELISA method em-
ploying the 15B4 anti-ceramide antibody to detect ceramide.
This antibody also detects dihydro-ceramide. All other studies
employed mass spectrometry, kinase assays, or staining with
an antibody against ceramide (from Glycobiotech), which does
not detect dihydroceramide or an unbiased metabolomic
approach. The mouse models between the studies also differ,
since Guilbault et al. (2009) used mice completely deficient for
Cftr, which had to be fed with a Peptamen (Nestle) diet to allow
survival. However this diet is inappropriate for use in rodents,
since mice consume as much as 75% of their body weight
per day of Peptamen, resulting in liver steatosis and dramatic
changes of the lipid metabolism (Borowitz et al., 2005) and
even a Niemann-Pick type-C phenotype, with a concomitant
change of acid sphingomyelinase activity (Bhuvaneswaran
et al., 1985). It might be possible that the accumulation of cer-
amide is observed in mice that are not severely sick, because
expression of Cftr is specifically restored in the intestine, while
a very severe phenotype with complete deficiency may alter
the accumulation of ceramide and switch to an accumulation
of dihydroceramide. Such an explanation of a further shift of
the ceramide metabolism in CFmice is also suggested by recent
studies from Duchesneau et al. (2017), who demonstrated a
decrease of ceramide in 8-month-old Cftr-deficient mice. Thus,
underlying exposure to bacteria, the diet, and the severity of
the disease may have an influence on the distribution of cer-
amide and dihydroceramide in CF lungs.10 Cell Host & Microbe 21, 1–12, June 14, 2017Our findings also suggest several potential approaches to
reducing the incidence and severity of P. aeruginosa infections,
which are the leading cause of death for patients with CF, or
even preventing these infections. Inhalation treatment with anti-
b1-integrin antibodies or RGD may be an effective therapy for
the prevention of pulmonary P. aeruginosa infections. Further-
more, we found that normalizing ceramide levels with pharmaco-
logical inhibitors of Asm activity corrects aberrant expression
of luminal b1-integrin and thereby prevents infection. Clinical
studies with systemic application of amitriptyline have already
been initiated and have yielded promising results (Riethm€uller
et al., 2009; N€ahrlich et al., 2013; Adams et al., 2016). Inhalation
of sphingosine prevents and cures P. aeruginosa infections in
CFmice but does not seem to influence inflammation in CF lungs
(Pewzner-Jung et al., 2014). Finally, inhalation of recombinant Ac
by Cf patients might simultaneously correct both the ceramide
accumulation and the sphingosine deficiency, thereby correcting
the ectopic b1-integrin expression. This is even more attractive
given our data showing that CF patients have a severe deficiency
of theAcprotein in their airways. Thesemethods suggest realistic
treatment options for patients with CF.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Materials
Polyps from healthy and CF persons were surgically removed, fixed in 4% phosphate-buffered saline (PBS)-buffered paraformalde-
hyde (PFA), embedded in paraffin, dewaxed, sectioned, and stained (see section below on Immunohistochemistry of Human
Samples). Biopsies from explanted CF or remaining donor lungs were also fixed in 4% PFA. Nasal epithelial cells were obtained
from CF-patients and healthy volunteers by nasal brushing and freshly used as described below. Primary bronchial epithelial cells
were obtained from explanted CF lungs and were isolated as previously described (Brodlie et al., 2010b) or from bronchial brushings
of non-CF donors.We used samples from female andmale patients. The identity of the patients and donors, respectively, was blinded
to the investigators. The studieswere approved by the local ethics committees Essen, Tuebingen andNewcastle andNorth Tyneside,
all patients gave informed consent. The permission numbers were 17-7326-BO, 08-3710, 214-003581-25, 01/179 and 11/NE/0291.
Mice
B6.129P2(CF/3)-CftrTgH(neoim)Hgu (CFMHH) congenic mice were produced by inbreeding the original CftrTgH(neoim)Hgu mutant mouse,
which was generated by insertional mutagenesis in exon 10 of the Cftr gene (Charizopoulou et al., 2004, 2006). This congenicCftrMHH
strain was then backcrossed for more than 10 generations into the B6 background. Because these mice still express low levels of
Cftr, they can be fed a standard mouse diet. They exhibit normal development but also display pulmonary pathology typical of CF
(Teichgr€aber et al., 2008; Zhang et al., 2010; Becker et al., 2010, 2012; Ulrich et al., 2010). Syngenic B6 mice were used as controls.
Further, we used Cftrtm1Unc-Tg(FABPCFTR) mice (Cftr/; Jackson Laboratory, Bar Harbor, ME, USA) backcrossed for more than 10
generations onto the C57BL/6 background. These mice are deficient in Cftr in all organs except the intestine, where they express
human CFTR under the control of a fatty acid binding protein (FABP) promoter. The transgene prevents intestinal obstruction and
allows the mice to eat a normal diet. B6 mice were again used as controls. No important differences were observed in the present
experiments, which used both the Cftr/ and the CftrMHH strains.
To create mice deficient in Cftr and heterozygous for Asm, we crossed Cftr/mice with C57BL/6 mice lacking Asm (gene symbol
Smpd1) (Horinouchi et al., 1995) to obtain B6-Cftrtm1Unc-Tg(FABPCFTR)Smpd1/ mice (Teichgr€aber et al., 2008). Syngenic B6 and
Cftr/mice were used as controls. For downregulation of ceramide production via Asm inhibition, mice were treated with two func-
tional inhibitors of Asm: amitriptyline hydrochloride (Sigma, #8404-25G) and fluoxetine (Ratiopharm GmbH, #PZN-3971342)
(Teichgr€aber et al., 2008). Amitriptyline (10 mg/kg; dissolved in 0.9% NaCl) was administered via intraperitoneal injection every
12 hr for a total of five doses, and mice were sacrificed within 6 hr after the final injection. Fluoxetine was dissolved in drinking water
(120 mg/L), which was changed every 2 days for more than 21 days.
To create overexpressing Asm-transgenic mice (Gulbins et al., 2013), we expressed murine Smpd1 cDNA under control of the
ubiquitous CAG promoter (cytomegalovirus [CMV] immediate-early enhancer/chicken b-actin promoter fusion). A loxP-flanked
STOP cassette was included between the promoter and the transgene. The conditional transgene was introduced into the deleted
Hprt gene locus of E14 embryonic stem cells. The transgenic mice were backcrossed to C57BL/6 mice for at least 10 generations.
The strain name is B6-Smpd1fl-tr/fl-tr. In the present study we expressed the transgene constitutively by crossing the mice with E2A-
Cre mice expressing Cre recombinase under the control of an E2A promoter (kindly provided by Dr. R. Waldsch€utz). To obtain het-
erozygous acid ceramidase 1 (Asah1)-deficientmice (Gulbins et al., 2013), we constructed a targeting vector containing the following:
homology regions of genomic Asah1 sequences in the C57BL/6J genetic background, a long homology region of 5.8 kb and a short
homology region of 1.7 kb, two loxP sites flanking Asah1 exon 1, a neomycin gene flanked by flippase recognition target (FRT) sites
for positive selection (the FRT-flanked selection cassette was removed in vivo with recombinase), and a diphtheria toxin A negative-
selection marker for reducing the isolation of non-homologous recombined embryonic stem (ES) cell clones and enhancing the isola-
tion of ES cell clones harboring the distal loxP site. The targeting vector was transfected into C57BL/6 embryonic stem cells by ho-
mologous recombination to obtain B6-Asah1fl-del/fl-del. Mice heterozygous for Ac gene knockout allele were generated by crossing
with E2A-Cre mice.e2 Cell Host & Microbe 21, 1–12.e1–e8, June 14, 2017
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equal size (usually 3-4 mice) by animal unit technical staff with no involvement in study design. Cages were randomly assigned to an
experimental group. The investigators were blinded to the group allocation during the experiment and/or when assessing the
outcome.
Mice were housed and bred within isolated cages in the mouse facility of the University Hospital, University of Duisburg-Essen,
Germany and of the University of Cincinnati. They were repeatedly tested for a panel of common murine pathogens according to
the 2002 recommendations of the Federation of European Laboratory Animal Science Associations. The mice were free of all path-
ogens. Procedures performed on the animals were approved by the Bezirksregierung Duesseldorf, Duesseldorf, Germany and the
IACUC committeee Cincinnati. Permission numbers are: G1380-13, G1376-13, G1121-10, AZ 84.02.04.2015.A064 and 10-05-10-01
METHOD DETAILS
Antibodies and Reagents
Human b1-integrin was stained with rabbit anti-human b1-integrin antibodies (#Ab52971; Abcam) and labeled with secondary Cy3-
coupled anti-rabbit F(ab)2 fragments (#711-166-152; Jackson ImmunoResearch). Paraffin-embedded mouse tissues were stained
with rat anti-mouse b1-integrin antibodies (clone MB1.2, #MAB1997; Merck Millipore) followed by incubation with Cy3-coupled
anti-rat F(ab)2 fragments (#712-166-153; Jackson ImmunoResearch). Acid ceramidase was stained with Cy3-coupled anti-acid ce-
ramidase antibodies (#4741, ProSci). In vivo binding of b1-integrin was achieved by application, injection or inhalation of the anti-b1-
integrin antibody clone 9EG7 (1 mg/ml; #550531; BD Biosciences). Isotype-matched antibodies were used as controls. These were
mouse IgM for the antibodies against sphingosine and ceramide, rat IgG2 for the staining with anti-integrin antibodies and purified
rabbit IgG for the stainings with anti-acid ceramidase (mouse IgM and purified rabbit IgG fromDako, rat IgG2 fromR&D). All ceramide
or sphingosine stainings were performed with the monoclonal mouse anti-ceramide antibody (clone S58-9, #MAB_0011, Glycobio-
tech), or monoclonal mouse anti-sphingosine antibody (clone NHSPH, #ALF-274042010, Alfresa Pharma Corporation), which were
visualized with Cy3 donkey anti-mouse IgM F(ab)2 fragments (#715-166-020; Jackson ImmunoResearch) or Cy5-coupled donkey
anti-mouse IgM antibody (#715-176-020; Jackson ImmunoResearch). GRGDNP peptide was obtained from Enzo Life Sciences
(#P-700). GRADSP peptides (Bachem, #H-7630) served as controls.
Bacteria
We used the previously described laboratory strain American Type Culture Collection (ATCC) 27853 P. aeruginosa, a clinical
P. aeruginosa isolate 762 (Grassme´ et al., 2000, 2003) and two mucoid isolates from individuals with CF, P. aeruginosa strains
1242 and 1245. Bacteria were plated from frozen stocks on fresh tryptic soy agar plates (TSA; Becton Dickinson) and grown at
37C for 14 to 16 hr. The strains 762 and ATCC 27853 were resuspended in 40 mL tryptic soy broth (Becton Dickinson), warmed
to 37C, to an optical density of 0.225 at 550 nm. The bacterial suspension was then incubated at 37C for 1 hr with shaking at
125 rpm to obtain bacteria in the early logarithmic growth phase. Bacteria were then washed twice and resuspended in warmed
RPMI 1640 medium (Invitrogen) supplemented with 10 mM HEPES. The final concentration of bacteria was quantified by photo-
spectrometry. The twomucoidP. aeruginosa strains 1242 and 1245were directly taken from the plate, resuspended and immediately
used for infection to ensure the mucoid form.
Inhalation Experiments
Mice inhaled 0.8mL of 325 mMRGDpeptides (GRGDNP) or 20 mg/ml anti-b1-integrin antibody 9EG7 diluted in 0.9%saline via amodi-
fied PARI BOY nebulizer device (PARI GmbH, Starnberg, Germany), as previously described (Teichgr€aber et al., 2008; Pewzner-Jung
et al., 2014). Control animals received 0.8mL nebulized 0.9% saline. Although the nebulizer was loaded with 0.8mL NaCl ± peptides/
antibodies, the mice only inhaled approximately 0.08 mL (i.e., also 10% of the drugs) over the 10 min inhalation period, while the ma-
jority of the fluid got lost in the device or around the nose of the mouse.
Mice were sacrificed 15 min after inhalation to detect surface b1-integrin in situ. For determination of the effects of GRGDNP pep-
tides or anti-b1-integrin antibody 9EG7 on the internalization of ceramide, sphingosine, and b1-integrin, mice were sacrificed 60 min
after inhalation.
In Vivo Infection Experiments
Mice were infected with 762 or ATCC 27853 P. aeruginosa strains 60 min after inhalation. Mice were lightly anesthetized with diethyl
ether, an agent that does not affect ciliary function (Forbes andHorrigan, 1977; Teichgr€aber et al., 2008).P. aeruginosawere prepared
as described above and resuspended in RPMI 1640 plus 10 mM HEPES to a final concentration of 53 107 or 53 106 CFU in 20 mL
medium. Themice were then inoculated with 53 107 or 53 106 CFU P. aeruginosa 762 or ATCC 27853 via a plastic-coated 30-gauge
needle, which was inserted 2 mm into the nose. Bacteria in mouse lungs were counted 4 hr after infection. Mice were sacrificed; the
lungs were removed, homogenized, and lysed in 5mg/mL saponin to release intracellular bacteria. Samples were then centrifuged at
3200 rpm to pellet all bacteria, washed in sterile PBS, diluted, and plated in duplicate onto TSA plates for 12 hr. Bacterial numbers
were counted; the counts represented the number of bacteria in whole-lung samples. This method of infection evaluates mucociliary
clearance more accurately than do other pulmonary infection models, such as intratracheal infection.Cell Host & Microbe 21, 1–12.e1–e8, June 14, 2017 e3
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5 times on consecutive days. Mice were then inhaled 1 hr after the last infection with acid ceramidase, sphingosine or RGD-peptides
and the number of the CFU in the lung was determined 5 hr later (6 hr after infection). Alternatively, the mice were treated with acid
ceramidase, sphingosine or RGD-peptides 2 days after the last of 5 infectionswithP. aeruginosa strains 1242 or 1245 and the number
of the bacteria in the lungs were determined after an additional 48 hr. Finally, we inhaled mice first with acid ceramidase, sphingosine
or RGD and infected them 1 hr later with 53 107 CFU P. aeruginosa strains 1242 or 1245. Bacterial CFU in the lung were determined
6 hr later.
In addition, we determined the number of bacteria in the lower third of the trachea 15, 30, 45, and 60 min after infection with 105
CFU; the sum of these counts represented the cumulative number of bacteria reaching the lower third of the trachea within 1 hr after
initiation of infection. This number reflects the clearance of the bacteria in the upper airways.
Immunohistochemistry of Mouse Lungs
Stainings were performed as previously reported (Grassme´ et al., 2001, 2003; Teichgr€aber et al., 2008; Pewzner-Jung et al., 2014).
For immunohistochemical evaluation ofmurine lungs,micewere sacrificed by cervical dislocation andwere immediately perfused via
the right heart with ice-cold normal saline for 2 min followed by cardiac perfusion with 4% PBS-buffered paraformaldehyde (PFA,
#0335.3, Roth) for 10 to 15 min. After being cleared of blood and fixed, the lungs were removed and further fixed in 4% PFA for
24 to 36 hr. The tissue was serially dehydrated with an Ethanol to Xylol gradient and then embedded in paraffin. Samples were
sectioned at 7 mm, dewaxed, rehydrated, and treated with pepsin (Digest All; #003009, Invitrogen) for 15 min (b1-Integrin) or
30 min (acid ceramidase, ceramide and sphingosine) at 37C. They were then washed with water and PBS and blocked for
10 min at room temperature with PBS, 0.05% Tween 20 (Sigma), and 5% fetal calf serum (FCS). The samples were stained with a
rat anti-mouse b1-integrin (1:100 dilution, clone MB1.2, Merck Millipore), anti-acid ceramidase (1:100 dilution), anti-ceramide
(1:100 dilution), anti-sphingosine (1:1000 dilution), anti-mouse b2-integrin antibodies (1:100, clone M1812, 1:100, #557437, BD) or
FITC-Annexin (1:200, #11 828 681 001, Roche) in H/S (132 mM NaCl, 20 mM HEPES [pH 7.4], 5 mM KCl, 1 mM CaCl2, 0.7 mM
MgCl2, 0.8mMMgSO4) plus 1%FCS at room temperature for 45min. Samples werewashed three timeswith PBS plus 0.05%Tween
20 and once with PBS. The tissue was secondarily labeled with Cy3-coupled anti-rat/rabbit/mouse F(ab)2 fragments (Jackson
Immunoresearch) in H/S plus 1% FCS for 30 min. Tissue was again washed three times with PBS plus 0.05% Tween 20 and
once with PBS; finally, they were embedded in Mowiol. Samples were evaluated by confocal microscopy as described below.
In experiments involving the intraluminal administration of rat anti-mouse b1-integrin antibody 9EG7 to mice, mice were anesthe-
tized, 1 mg of the antibody in 10 mL H/S was slowly injected into the lung via the trachea and allowed to bind for 15 min, the mice were
sacrificed by cervical dislocation, the lungs were washed 10-times with PBS via bronchioalveolar lavage, and 1 mL of 2% PBS-buff-
ered PFA (pH 7.4) was instilled into the lung. After 15 min of fixation, the lungs were removed and further fixed in 4% PBS-buffered
PFA for 24 to 36 hr, dehydrated, embedded, and sectioned as above. Stainings were carried out by rehydrating the samples and
treating them with Proteinase K (dilution 1:1000 in 30 mM Tris HCL; pH 8.0, #03115828001, QIAGEN) for 10 min at 37C. They
were washed with water and PBS and then directly stained with Cy3-coupled anti-rat F(ab)2 fragments for 30 min. Slides were again
washed three times in PBS plus 0.05% Tween 20 and once with PBS. Samples were embedded in Mowiol and evaluated with
confocal microscopy as described below.
All immunostainings were controlled with isotype control antibodies that showed no or very weak staining. These were mouse IgM
for the antibodies against sphingosine and ceramide, rat IgG2 for the staining with anti-integrin antibodies and purified rabbit IgG for
the stainings with anti-acid ceramidase (mouse IgM and purified rabbit IgG fromDako, rat IgG2 fromR&D). We also included controls
with secondary Cy3-coupled antibodies only. Further controls were stainings with FITC-Annexin and stainings with anti-b2-integrin
antibodies as above.
Immunostainings of Human Samples
Human nasal polyps or lung tissues were fixed in 4% PFA/PBS for 48 hr. Samples were dehydrated and embedded in paraffin,
sectioned at 7 mm, dewaxed, rehydrated, and treated with pepsin solution for 7 min for anti-human b1-integrin antibodies (Abcam),
for 40 min for anti-ceramide antibodies and 30min for anti-sphingosine antibodies. Isolated nasal epithelial cells were first treated as
described below, washed and then fixed in 1% PFA/PBS for 10 min and washed in PBS. All samples were blocked with PBS plus
0.05% Tween 20 and 5% FCS at room temperature for 10 min. The samples were washed and stained with either rabbit anti-human
b1-integrin antibody (Abcam) (1:75 dilution), anti-ceramide (1:100), anti-acid ceramidase (1:100) or anti-sphingosine antibodies
(1:1000) in H/S buffer plus 1% FCS for 45 min at room temperature. Histologies were washed 3-washed in PBS plus 0.05% Tween
20 and again in PBS. Cells were washed 3-times in PBS. The antibodies were secondarily labeled with Cy3-coupled anti-rabbit IgG,
or anti-mouse IgM F(ab)2 fragments. They were diluted in H/S plus 1%FCS and incubated in the dark for 30min. The tissue was again
washed as above before being embedded in Mowiol.
Human Nasal Epithelial Cells
Cells were isolated from CF patients and healthy controls (age and sex matched) using a nasal brush. The cells were incubated in
RPMI-1640 containing 1% FCS, 1 mM HEPES (pH 7.4), 0.2 mM L-glutamine, 0.1 mM sodium pyruvate, 10 mM nonessential amino
acids for 4 hr at 4C with RGD-peptides, anti-human active b1-integrin antibody (1:100, clone HUTS-4, #MAB2097Z, Millipore), acid
ceramidase (25 units), 1 mM micellar sphingosine (#271048, Avanti Polar Lipids) or left untreated. Cells were incubated for ane4 Cell Host & Microbe 21, 1–12.e1–e8, June 14, 2017
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PFA/PBS for immunostainings. The cells were then washed twice in H/S, blocked by 15 min incubation in H/S + 5% FCS, washed
once and stained with anti-sphingosine, anti-ceramide or anti-acid ceramidase antibodies, rabbit anti-human anti-b1-integrin anti-
body (1:100, #Ab52971; Abcam) or isotype controls. The samples were washed twice. All samples were incubated with the appro-
priate Cy3-labeled secondary antibody as above. Samples were washed again twice and the cells were embedded in Mowiol for
confocal microscopy analysis. An aliquot of all samples treated with RGD-peptides, anti-integrin-antibodies, acid ceramidase or
sphingosine or left untreated was washed in H/S and infected with P. aeruginosa strains ATCC 27853 or 762 for 60 min at an mul-
tiplicity of infection of 1 cell: 0.5 bacteria in H/S. Samples were plated on LB-agar and colonies were counted after overnight growth.
Human Bronchial Epithelial Cells
Primary bronchial epithelial cells were cultured at an air liquid interface (Brodlie et al., 2010b). 13 105 cells/mL in 0.5 mL of bronchial
epithelial growth medium were seeded into the apical chamber of the 12 mm Transwell inserts coated with type IV collagen with
1.5 mL media in the basal chamber. Following cell attachment apical medium was removed and the basal medium switched to
air liquid interface specific media, essentially a 50:50 mixture of bronchial epithelial growth medium with DMEM-H (Fulcher et al.,
2005). Cells were cultured for 24 days to allow proper differentiation and polarization, which was determined by the presence of
ciliated and mucus-secreting cells.
Confocal Microscopy
Samples were examined with a Leica TCS-SP5 confocal microscope equipped with a 100 3 lens, and images were analyzed with
Leica LCS software version 2.61 (Leica Microsystems, Mannheim, Germany). All comparative samples were measured at identical
settings.
b1-Integrin Immunoprecipitations
To demonstrate ectopic expression of b1-integrin on the luminal surface of the trachea, we removed the trachea, opened it, and incu-
bated the intact luminal surface on ice for 20 min with 4 mL of anti-b1-integrin antibodies, clone MB1.2. The samples were washed
extensively; lysed in 125 mM NaCl, 25 mM Tris HCl (pH 7.4), 10 mM EDTA, 10 mM sodium pyrophosphate, 3% Nonidet P40, and
10 mg/ml aprotinin and leupeptin for 5 min at 4C. They were then centrifuged at 14,000 rpm. The immunocomplexes were immobi-
lized with protein A/G agarose (#sc-2003, Santa Cruz Inc.) for 45min, washed 6 times in lysis buffer, resuspended in 1x SDS-Laemmli
Sample buffer, and boiled for 5 min at 95C. Proteins were separated on 8.5% sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) gels, blotted with b1-integrin antibody clone MB1.2, and developed with an AP-coupled secondary antibody
and a chemoluminescence system.
Quantitative Surface Assays
Sphingosine
Mice were sacrificed, and the trachea was removed, opened, and placed on a 30C prewarmed plastic plate. The luminal surface of
the trachea was incubated with 0.001 units of sphingosine kinase 1 (#6068-SK-010, R&D) in 4 mL of 150mM sodium acetate (pH 7.4),
1 mMATP, and 10 mCi [32P]gATP. Controls were incubated with the same buffer without sphingosine kinase or were left untreated.We
ensured that the kinase buffer was added only to the luminal surface of the trachea. Nasal epithelial cells were washed, resuspended
in 150 mM sodium acetate (pH 7.4), 1 mM ATP, 10 mCi [32P]gATP and 0.001 units of sphingosine kinase and incubated for 30 min at
37C. The sphingosine kinase reaction was terminated by adding 100 mL H2O, followed by the addition of 20 mL 1N HCl, 800 mL
CHCl3:CH3OH:1N HCl (100:200:1, v:v:v), and 240 mL each of CHCl3 and 2 M KCl. The lower phase was collected, dried, dissolved
in 20 mL CHCl3:CH3OH (1:1, v/v), and separated on Silica G60 TLC plates with CHCl3:CH3OH:acetic acid:H2O (90:90:15:5, v:v:v:v)
as a developing solvent. The TLC plates were analyzed with a phosphoimager. Surface sphingosine levels were determined with
a standard curve of C18-sphingosine.
Ceramide
The intact epithelial surface of the trachea was incubated with 0.01 units diacylglycerol (DAG) kinase (#BML-SE100, Enzo) in 4 mL of
150 mM sodium acetate (pH 7.4), 1 mM adenosine triphosphate (ATP), and 10 mCi [32P]gATP for 15 min at 30C. Controls were incu-
bated with the same buffer without kinase or were left untreated. Nasal epithelial cells were washed, resuspended in 150mM sodium
acetate (pH 7.4), 1 mM ATP, 10 mCi [32P]gATP and 0.01 units of diacylglycerol kinase and incubated for 30 min at 37C. The kinase
reaction was terminated by transferring the trachea into CHCl3:CH3OH:1N HCl (100:100:1, v/v/v), followed by the addition of 170 mL
buffered saline solution (135 mMNaCl, 1.5 mMCaCl2, 0.5 mMMgCl2, 5.6 mM glucose, 10 mMHEPES; pH 7.2) and 30 mL of 100 mM
EDTA. Lipids were extracted, separated by Silica G60 thin-layer chromatography (TLC), and analyzedwith liquid scintillation counting
and a standard curve of C16- to C24-ceramides, as previously described (Grassme´ et al., 2003; Teichgr€aber et al., 2008; Pewzner-
Jung et al., 2014).
Surface Activity of Acid Ceramidase
We injected 4 mL [14C16]ceramide (55 mCi/mmol, #ARC-0831, ARC) into the lumen of the trachea of anesthetized mice. Before injec-
tion, [14C16]ceramide was dried, resuspended in 0.05% octylglucopyranoside in 150 mM sodium acetate (pH 7.4 or 5.0), and bath
sonicated for 10 min. After 20 min, mice were sacrificed, the trachea was carefully removed and extracted in H2O andCell Host & Microbe 21, 1–12.e1–e8, June 14, 2017 e5
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rated by TLC with CHCl3:CH3OH:NH4OH (90:20:0.5, v/v/v), and analyzed with a Fuji Imager. Injection of 4 mL of the acid ceramidase
inhibitors N-oleoylethanolamine (0.5 mM, #00383, Sigma) or carmofur (1 mM, #14243, Cayman Chemicals) onto the trachea was per-
formed 15 min before the injection of [14C16]-ceramide and served to demonstrate the contribution of acid ceramidase to the
observed ceramide consumption.
Acid Ceramidase Activity
Human nasal epithelial cells
Cells were lysed in 1% Nonidet P40 (NP40) in 150 mM sodium acetate (pH 4.5) for 5 min on ice, diluted to 0.1% NP40 in 150 mM
sodium acetate (pH 4.5) and 0.3 mCi/sample [14C16]ceramide (ARC0831, 55 mCi/mmol) was added. To this end, the [
14C16]ceramide
was dried for 10min, resuspended in 0.1%OGP in 150mMsodium acetate (pH 4.5) and bath sonicated for 10min. The samples were
incubated at 37C for 60 min. The reaction was terminated by extraction in H2O and CHCl3:CH3OH:HCl (100:100:1, v/v/v). The lower
phase was dried, and samples were resuspended in CHCl3:CH3OH (1:1, v/v), separated by TLC with CHCl3:CH3OH:NH4OH
(90:20:0.5, v/v/v), and analyzed with a Fuji Imager.
Human bronchial epithelial cells
Air-liquid interface cultures were mechanically scraped from the Transwell surface and were lysed in 1% Nonidet P40 (NP40) in
150 mM sodium acetate (pH 4.5), kept for 5 min on ice and diluted to 0.1% NP40 in 150 mM sodium acetate (pH 4.5). Lysates
were incubated with BODIPYTR ceramide at 37C for 30 min, extracted, samples were separated by thin layer chromatography
as above and analyzed on a Typhoon fluorescence plate reader.
Acid Ceramidase Western Blots
Mice were sacrificed, and the trachea was removed. Epithelial cells were carefully scraped from the inner surface of the trachea.
These cells were pelleted and lysed in 125 mM NaCl, 25 mM Tris HCl (pH 7.4), 10 mM EDTA, 10 mM sodium pyrophosphate, 3%
Nonidet P40, and 10 mg/ml aprotinin and leupeptin for 5 min at 4C. They were then centrifuged at 14,000 rpm. Lysates were added
to 5x SDS sample buffer, and proteins were separated by 12.5% SDS-PAGE, blotted, and developed with anti-acid ceramidase an-
tibodies and ECL.
Internalization of FITC-Coupled RGD
WT or CF mice were inhaled with FITC-coupled RGD as above. Tracheal epithelial cells were isolated 30 min later and analyzed by
confocal microscopy.
Flow Cytometry Studies
To induce internalization of b1-Integrin or Art1, the intact surface of the trachea was incubated with anti-b1-integrin-antibodies
(9EG7), anti-b1-integrin-antibodies (9EG7) that were already immobilized to protein A/G agarose, anti-Art1-antibodies (#sc-20255,
Santa Cruz Inc.), anti-ceramide or isotype control antibodies for 30, 60 or 90 min at 37C. The samples were washed and the surface
was then incubated with 1 mg/mL anti-b1-Integrin-(clone MB1.2) or anti-Art1-antibodies (1:100,) for 30 min at 4C, washed exten-
sively in H/S and the surface was incubated for 30 min with a FITC-coupled secondary antibody. Controls were immediately incu-
bated with 1 mg/mL of each anti-b1-Integrin-(clone MB1.2) or anti-Art1-antibodies for 30 min at 4C. Acid ceramidase (100 units/
mL), N-oleoylethanolamine (0.5 mM) or carmofur (1 mM) were added 15min prior to the antibodies. C16 ceramide (10 mM) was added
to the surface of WT trachea for 30 min at 37C prior to staining with anti-b1-Integrin-antibodies cloneMB1.2. The trachea was finally
washed again and epithelial cells were scraped from the surface. To obtain a single cell suspension, the samples were incubated for
5 min with trypsin at 37C, washed in cold H/S and analyzed on a FASC-Calibur. The mean fluorescence (MFI) intensity of 10 000
signals was determined. In addition, the isolated tracheal surface was infected with 104 CFU P. aeruginosa strains ATCC 27853
or 762 for 15 or 30 min, washed, incubated with anti-b1-Integrin-antibodies clone MB1.2 and analyzed as above for surface
expression of b1-Integrin.
Acid Sphingomyelinase Activity
WT or CF tracheae were infected with 104 CFU P. aeruginosa for 15 min, washed and tracheal epithelial cells were carefully scraped
from the trachea surface. Cellswere pelleted, lysed in in 250mLof a buffer consisting of 250mMsodiumacetate (pH5.0) and 0.1%NP-
40andsonicated3-times for 10 seachwith a tip sonicator at 4C.Sampleswere incubatedwith 25nCiper sample [14C]-sphingomyelin
(52 mCi/mmol, #NEC 663010UC, Perkin Elmer) for 60 min at 37C. The substrate was dried prior to use, resuspended in 250 mM
sodium acetate (pH 5.0) and 0.1% NP-40, bath sonicated for 10 min and an aliquot of 30 mL was added to the lysates. Samples
were extracted in 800 mL chloroform/methanol (2:1, v/v), phases were separated by centrifugation and radioactivity of the aqueous
phase was measured by liquid scintillation counting to determine the release of [14C]phosphorylcholine from [14C]sphingomyelin.
Degradation and Uptake Kinetics
Tracheal surface proteins were biotinylated for 30 min using a labeling kit (Pierce) following the instructions of the vendor. Samples
were kept in a humidified chamber at 37C. Samples were then incubated with 100 units/mL acid ceramidase or 1 mg/mL RGD-pep-
tides for 30, 60 or 90 min or left untreated.e6 Cell Host & Microbe 21, 1–12.e1–e8, June 14, 2017
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HCl (pH 7.4), 10 mM EDTA, 10 mM sodium pyrophosphate, 3% Nonidet P40, and 10 mg/ml aprotinin and leupeptin for 5 min at 4C,
insoluble material was pelleted and b1-Integrin was precipitated using Streptavidin-coupled agarose. Blots were developed with
anti-b1-Integrin antibodies (clone MB1.2) and HRP-coupled secondary antibodies (Santa Cruz Inc.).
To determine internalization, samples were washed in H/S after biotinylation and furher incubations as indicated and the intact tra-
chea surface was incubated with anti-b1-Integrin antibodies clone MB1.2 for 30 min at 4C, washed in H/S, lysed as above, immu-
nocomplexes were immobilized using protein A/G agarose, eluted into 1x SDS-sample buffer, separated on SDS-PAGE, blotted and
developed with HRP-coupled streptavidin (BioRad). Actin blots were performed from aliquots of the total lysates prior to immuno-
precipitation and served as loading controls.
In Vitro Infection of Trachea Surfaces
Trachea were carefully excised and incubated with 200 CFU of P. aeruginosa 762, ATCC27853 or 1242 for 60 min. The bacteria were
applied in a volume of 3 mLH/S to the surface of the trachea, the tracheawas placed in a humidified chamber and incubated for 60min
at 37C. The samples were then transferred into 100 mL TSB medium, the tissue was homogenized and the samples were plated on
LB agar plates. Colonies were counted after overnight growth.
Sphingosine (10 mM), acid ceramidase (100 units/mL), octylglucopyranoside (OGP, 0.01%), anti-sphingosine antibodies (1 mg/mL)
or sphingosine kinase (0.001 units) were added 15 min prior to the bacteria and washed off before adding the bacteria. Sphingosine
was suspended in 10% OGP. Cells were permeabilized with 0.1% Triton X-100 in H/S for 5 min, washed in H/S, treated with 10 mM
sphingosine, 100 units/mL acid ceramidase, 0.01% OGP or left untreated and then infected. PFA (0.25%) was added for 10 min, the
samples were then extensively washed, treated with sphingosine, acid ceramidase, OGP as above or left untreated and infected.
Ceramide-b1-Integrin Association
Trachea were exposed, incubated in vitro as indicated, washed in H/S, anti-b1-Integrin antibodies clone MB1.2 (1 mg/mL) were
added and incubated at 4C for 30 min. The samples were washed and disrupted by 3 rounds of sonication with a tip sonicator,
10 s each. Nuclei were pelleted by centrifugation at 800xg for 5 min. The supernatants were collected and anti-b1-Integrin antibodies
or isotype control antibodies (rat IgG) were immobilised on protein A/G agarose for 30 min at 4C, washed 5 times in H/S and sub-
jected to a ceramide kinase assay. To degrade ceramide within the samples, we added 100 units/mL acid ceramidase and incubated
at 37C for 15 min.
Inhalation of Anti-sphingosine Antibodies
Mice inhaled 0.8 mL of 2 mg/ml monoclonal anti-sphingosine antibodies diluted in 0.9% saline via a modified PARI BOY nebulizer
device (PARI GmbH). Mice were infected 45 min after inhalation of the anti-sphingosine antibodies with 5x107 CFU of
P. aeruginosa strain 762 or 1x108 CFU of strains ATCC 27853 or 1242. Bacterial numbers in the lung were determined 6 hr after
the infection.
Gr1, P. aeruginosa, and Hemalaun Stainings
Lung paraffin sections were dewaxed, blocked as above, immunostained for 45 min with anti-GR1-antibodies (anti-Ly-6G/Ly-6C,
#553122, BD) diluted 1:200 in H/S plus 1% FCS. Samples were washed 3-times in PBS plus 0.05% Tween 20, stained for 45 min
with anti-P. aeruginosa antibodies (1:1000, #AP086, Biotrend) subsequently incubated for 45 min with FITC-coupled anti-rat IgG
and Cy3-coupled anti-guinea pig antibodies. Finally, the samples were stained for 5 min with hemalaun. Samples were embedded
in mowiol and analyzed on a Leica DMIRE2.
In Vitro Incubation with Sphingosine
A 2 mM stock solution of D-erythro-sphingosine (d18:1, Avanti Polar Lipids) in 10% octylglucopyranoside was sonicated in a bath
sonicator for 10 min immediately prior to addition to the bacteria to achieve micelle formation. All P. aeruginosa strains were cultured
overnight on TSA plates, the P. aeruginosa strains 762 and ATCC 27853 were then cultured at an OD of 0.2 for 1 hr in TSB to obtain an
early logarithmic growth phase. The mucoid P. aeruginosa strains 1242 and 1245 were directly taken from the agar plate. All bacteria
were diluted in airway surface liquid (ASL)-buffer consisting of 10 mM HEPES, 63 mM NaCl, 2.4 mM KCl, 1.2 mM CaCl2, 1.9 mM
MgSO4, pH 7.2. This buffer mimics the ion composition of the airway surface liquid (Baconnais et al., 1999). Sphingosine at the indi-
cated concentration was then immediately added to 1000 CFU of the P. aeruginosa strains 762, ATCC 27853, 1242 or 1245. Samples
were incubated for 60 min at 37C. An aliquot was then plated on LB plates, cultured o/n and the CFUs were counted.
Sphingosine in Tracheal Lavage
Trachea were isolated fromWT or CF mice and the tracheal surface washed with 200 mL ice-cold H/S. Samples were then extracted
in CHCl3/CH3OH/1N HCl (100:200:1, v/v/v), the lower phase was dried and resuspended in a detergent solution (7.5% [w/v] n-octyl
glucopyranoside, 5 mM cardiolipin in 1 mM diethylenetriamine-pentaacetic acid). The kinase reaction was initiated by addition of
0.001 units sphingosine kinase in 50 mM HEPES (pH 7.4), 250 mM NaCl, 30 mM MgCl2 1 mM ATP and 10 mCi [
32P]gATP. Samples
were incubated for 30 min at 37C with shaking (350 rpm) and processed as above. The volume was calculated from the area of the
trachea investigated and the published height of the airway surface liquid film (Tarran et al., 2001).Cell Host & Microbe 21, 1–12.e1–e8, June 14, 2017 e7
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Data are expressed as arithmetic means ± SD. For the comparison of continuous variables from independent groups we used
Student’s t test for two groups and one-way ANOVA for more than two groups followed by post hoc Student’s t tests for all pairwise
comparisons applying Bonferroni correction for multiple testing. The p values for the pairwise comparisons were calculated after
Bonferroni correction. All values were normally distributed. The statistical details (n-numbers, mean ± SD and tests) are given
in the figure legends. The sample size planning for the continuous variables in vivo infection experiments was based on two-sided
Wilcoxon-Mann-Whitney tests (software: G*Power Version 3.1.7 of the University of Duesseldorf, Germany). Investigators were
blinded for histology experiments and animal identity as described above. All data were quantified using ImageJ and are expressed
as arbitrary units (a.u.). In each photo 20 randomly chosen areas corresponding to the luminal membrane of 20 different cells were
quantified and averaged with the values obtained in the other photos of the fluorescencemicroscopy studies. Since the control stain-
ings with Cy3-coupled isotype control antibodies are very weak, we also show the light transmission pictures of hemalaun stainings.
DATA AND SOFTWARE AVAILABILITY
G*Power Version 3.1.7 of the University of Duesseldorf, Germany and ImageJ are public programs available online without charge.e8 Cell Host & Microbe 21, 1–12.e1–e8, June 14, 2017
